A dose-ranging randomized, open-label study evaluating the effect of bilateral intravitreal injection of GS010 at two dose levels on visual acuity and retinal mitochondrial activity in patients affected with ND4 Leber Hereditary Optic Neuropathy – The REVISE Study - GS-LHON-CLIN-08
Latest Information Update: 30 Mar 2026
At a glance
- Drugs Lenadogene nolparvovec (Primary)
- Indications Leber's hereditary optic atrophy
- Focus Therapeutic Use
- Acronyms REVISE
- Sponsors GenSight Biologics
Most Recent Events
- 20 Mar 2026 According to GenSight Biologics media release, the study has enrolled the next three patients.
- 09 Mar 2026 According to GenSight Biologics media release, the trial is progressing on schedule, with the second patient expected to be enrolled over the next few weeks.
- 02 Mar 2026 Status changed from not yet recruiting to recruiting.